Top 10 Biotech Stocks To Invest In 2019

Several analysts have recently updated their ratings and price targets for Concert Pharmaceuticals (NASDAQ: CNCE):

8/3/2018 – Concert Pharmaceuticals had its “buy” rating reaffirmed by analysts at HC Wainwright. 8/2/2018 – Concert Pharmaceuticals had its “buy” rating reaffirmed by analysts at Mizuho. They now have a $27.00 price target on the stock. They wrote, “We do not see earnings as the most meaningful indicator of value for a development-stage biotech. More importantly, Concert continues its steady progress on the clinical development front. A key catalyst is expected in 4Q18 with top-line readouts from the phase 2a trial of CTP-543 in alopecia areata at the 4 mg and 8 mg doses. A protocol amendment is also planned to evaluate the highest 12 mg dose. We anticipate data from the high-dose cohort will likely read out in 4Q19.”” 7/30/2018 – Concert Pharmaceuticals was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” rating. 7/24/2018 – Concert Pharmaceuticals was downgraded by analysts at ValuEngine from a “buy” rating to a “hold” rating. 7/17/2018 – Concert Pharmaceuticals was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating. 6/26/2018 – Concert Pharmaceuticals was downgraded by analysts at ValuEngine from a “strong-buy” rating to a “buy” rating.

Concert Pharmaceuticals opened at $16.60 on Friday, Marketbeat Ratings reports. The stock has a market cap of $396.42 million, a price-to-earnings ratio of 4.07 and a beta of 1.03. Concert Pharmaceuticals Inc has a 52-week low of $13.57 and a 52-week high of $30.71.

Top 10 Biotech Stocks To Invest In 2019: Biogen Idec Inc(BIIB)

Advisors’ Opinion:

  • [By Shane Hupp]

    ADAMCAPITAL Gestao de Recursos Ltda. lowered its holdings in Biogen Inc (NASDAQ:BIIB) by 30.5% in the 2nd quarter, HoldingsChannel reports. The fund owned 125,856 shares of the biotechnology company’s stock after selling 55,267 shares during the quarter. Biogen comprises approximately 1.8% of ADAMCAPITAL Gestao de Recursos Ltda.’s portfolio, making the stock its 16th largest holding. ADAMCAPITAL Gestao de Recursos Ltda.’s holdings in Biogen were worth $36,528,000 at the end of the most recent quarter.

  • [By Lee Jackson]

    This large-cap biotech will partner with Samsung Bioepis in the biosimilar world. Biogen Inc. (NASDAQ: BIIB) discovers, develops and delivers to patients worldwide innovative therapies for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders. Founded in 1978, Biogen is one of the world’s oldest independent biotech companies, and patients worldwide benefit from its leading multiple sclerosis (MS) and innovative hemophilia therapies.

  • [By Todd Campbell]

    PTC Therapeutics (NASDAQ:PTCT) shares took off after updated data from a trial evaluating risdiplam suggested it could mount a stiff challenge to Biogen’s (NASDAQ:BIIB) and Ionis Pharmaceuticals’ (NASDAQ:IONS) Spinraza for the treatment of  spinal muscular atrophy (SMA), a rare and life-threatening genetic disease. The data is solid, but a one-and-done SMA treatment is already in late-stage studies at Novartis’ (NYSE:NVS), and that therapy could become available as soon as 2019. 

Top 10 Biotech Stocks To Invest In 2019: Amgen Inc.(AMGN)

Advisors’ Opinion:

  • [By Max Byerly]

    Wedbush Securities Inc. decreased its holdings in Amgen, Inc. (NASDAQ:AMGN) by 5.5% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 20,159 shares of the medical research company’s stock after selling 1,174 shares during the quarter. Wedbush Securities Inc.’s holdings in Amgen were worth $3,721,000 at the end of the most recent reporting period.

  • [By Max Byerly]

    Amgen (NASDAQ: AMGN) and aTyr Pharma (NASDAQ:LIFE) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, earnings, risk, analyst recommendations and institutional ownership.

  • [By Keith Speights]

    It’s not too hard to find biotech stocks that are bargains right now. Two of the most attractively priced biotech stocks on the market are Amgen (NASDAQ:AMGN) and Gilead Sciences (NASDAQ:GILD). Both stocks also provide nice dividend yields for income-seeking investors.

  • [By Logan Wallace]

    Philadelphia Trust Co. decreased its holdings in Amgen, Inc. (NASDAQ:AMGN) by 8.0% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 74,676 shares of the medical research company’s stock after selling 6,501 shares during the quarter. Amgen makes up 1.2% of Philadelphia Trust Co.’s portfolio, making the stock its 22nd biggest position. Philadelphia Trust Co.’s holdings in Amgen were worth $13,784,000 as of its most recent SEC filing.

  • [By ]

    Amgen’s (NASDAQ:AMGN) past is filled with excitement. The company rose to become one of the biggest biotechs in the world. It grew a product lineup with multiple blockbuster drugs. Over the last decade, Amgen’s share price has more than tripled. But the excitement appears likely to diminish considerably for Amgen — at least for the next few years.

  • [By Cory Renauer]

    Lilly investors can also look forward to growing sales of the third new treatment for the prevention of migraine headaches. Emgality launched in October months after competing treatments from Amgen (NASDAQ:AMGN) and Teva Pharmaceuticals (NYSE:TEVA) late last year.

Top 10 Biotech Stocks To Invest In 2019: ArQule Inc.(ARQL)

Advisors’ Opinion:

  • [By Logan Wallace]

    BidaskClub upgraded shares of ArQule (NASDAQ:ARQL) from a hold rating to a buy rating in a report released on Saturday.

    A number of other research firms have also issued reports on ARQL. Roth Capital upped their price target on ArQule from $5.00 to $6.00 and gave the company a buy rating in a research report on Tuesday, April 17th. Leerink Swann upgraded ArQule from a market perform rating to an outperform rating in a research report on Thursday, April 5th. Zacks Investment Research lowered ArQule from a buy rating to a hold rating in a research report on Wednesday, April 4th. ValuEngine upgraded ArQule from a hold rating to a buy rating in a research report on Wednesday, May 2nd. Finally, B. Riley set a $4.00 price target on ArQule and gave the company a buy rating in a research report on Monday, March 26th. Seven analysts have rated the stock with a buy rating, The stock currently has an average rating of Buy and an average target price of $4.69.

  • [By Lisa Levin] Gainers
    Foot Locker, Inc. (NYSE: FL) rose 15.3 percent to $53.50 in pre-market trading after the company reported better-than-expected results for its first quarter.
    Evofem Biosciences, Inc. (NASDAQ: EVFM) rose 10.4 percent to $4.58 in pre-market trading. Evofem Biosciences reported closing of public offering of common stock and warrants.
    Resonant Inc. (NASDAQ: RESN) rose 7.3 percent to $4.88 in pre-market trading after declining 1.94 percent on Thursday.
    SolarEdge Technologies, Inc. (NASDAQ: SEDG) shares rose 5.7 percent to $59.65 in pre-market trading after falling 8.43 percent on Thursday.
    Yirendai Ltd. (NYSE: YRD) rose 5 percent to $30.00 in pre-market trading after reporting Q1 results.
    Deckers Outdoor Corp (NYSE: DECK) rose 4.9 percent to $108.75 in pre-market trading after reporteingd better-than-expected results for its fiscal fourth quarter.
    Blue Apron Holdings, Inc. (NYSE: APRN) rose 4.2 percent to $3.21 in pre-market trading after gaining 3.70 percent on Thursday.
    Recro Pharma, Inc. (NASDAQ: REPH) rose 4 percent to $5.85 in pre-market trading after dropping 54.67 percent on Thursday.
    ArQule, Inc. (NASDAQ: ARQL) rose 3.8 percent to $4.70 in pre-market trading after gaining 4.86 percent on Thursday.
    Babcock & Wilcox Enterprises, Inc. (NYSE: BW) shares rose 2.9 percent to $2.85 in pre-market trading after climbing 7.78 percent on Thursday.
    Bilibili Inc. (NASDAQ: BILI) shares rose 2.5 percent to $14.20 in pre-market trading after surging 11.33 percent on Thursday.

    Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.

  • [By Maxx Chatsko]

    Shares of development-stage biopharma ArQule (NASDAQ:ARQL) rose nearly 17% today after the company announced two appointments to its management team in two newly created positions. Dr. Marc Schegerin will serve as senior vice president, corporate strategy, communication, and finance. Dr. Shirish Hirani will serve as senior vice president, program management and product planning. 

  • [By Stephan Byrd]

    ArQule, Inc. (NASDAQ:ARQL) Director Ronald M. Lindsay acquired 23,900 shares of the company’s stock in a transaction on Thursday, May 10th. The stock was acquired at an average price of $2.67 per share, for a total transaction of $63,813.00. Following the purchase, the director now directly owns 43,900 shares of the company’s stock, valued at $117,213. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

  • [By Joseph Griffin]

    ArQule (NASDAQ:ARQL)‘s stock had its “buy” rating restated by equities researchers at Needham & Company LLC in a research report issued to clients and investors on Tuesday, Marketbeat Ratings reports. They currently have a $6.00 price target on the biotechnology company’s stock, up from their prior price target of $5.00. Needham & Company LLC’s price target suggests a potential upside of 134.38% from the company’s previous close.

  • [By Logan Wallace]

    ValuEngine downgraded shares of ArQule (NASDAQ:ARQL) from a strong-buy rating to a buy rating in a research report sent to investors on Saturday.

    Several other brokerages also recently issued reports on ARQL. Zacks Investment Research upgraded shares of ArQule from a hold rating to a buy rating and set a $2.75 target price for the company in a research note on Tuesday, May 8th. B. Riley set a $4.00 target price on shares of ArQule and gave the company a buy rating in a research note on Monday, March 26th. Roth Capital raised their target price on shares of ArQule from $5.00 to $6.00 and gave the company a buy rating in a research note on Tuesday, April 17th. BidaskClub upgraded shares of ArQule from a hold rating to a buy rating in a research note on Saturday, May 19th. Finally, Leerink Swann upgraded shares of ArQule from a market perform rating to an outperform rating in a research note on Thursday, April 5th. One research analyst has rated the stock with a sell rating, six have issued a buy rating and one has issued a strong buy rating to the company. The company has an average rating of Buy and a consensus price target of $5.35.

Top 10 Biotech Stocks To Invest In 2019: Alnylam Pharmaceuticals Inc.(ALNY)

Advisors’ Opinion:

  • [By Jim Crumly]

    Commercial success for Tegsedi is not a done deal even if it’s approved worldwide; Alnylam Pharmaceuticals’ (NASDAQ:ALNY) competing drug patisiran was approved by the FDA on Aug. 10. Alnylam’s clinical testing showed cardiac benefits for patients whose cardiovascular systems have been affected by the disease, and Alnylam believes that will give patisiran an advantage over Tegsedi. But in the conference call, Akcea executives brushed off that concern and pointed to the advantage Tegsedi has in being an injection that can be delivered at home, versus patisiran, which is administered intravenously in a clinic. We shall see.

  • [By Keith Speights]

    It’s not exactly David vs. Goliath. However, Bellicum Pharmaceuticals (NASDAQ:BLCM) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are definitely in different leagues right now. Both are clinical-stage biotechs, but Bellicum’s market cap is less than $350 million while Alnylam’s market cap is close to $10 billion.

  • [By Motley Fool Transcription]

    Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Q4 2019 Earnings Conference CallFeb. 7, 2017, 4:30 p.m. ET

    Contents:
    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:

    Operator

  • [By Brian Orelli]

    The delay in an FDA decision for Tegsedi puts it behind competitor Alnylam Pharmaceuticals (NASDAQ:ALNY), which expects to hear from the FDA by Aug. 11 for its hATTR drug patisiran. But Sarah Boyce, the president at Akcea Therapeutics, doesn’t think a few months will really matter: “We don’t really feel that’s going to have any impact and the drugs will be close enough together from a launch perspective. So not really [going] to make any adjustments, and we’re very well prepared to be ready to launch following approval.”

Leave a Reply

Your email address will not be published. Required fields are marked *